Brief: Camurus Says Co And Lilly Enter Collaboration And License Agreement For Long-Acting Fluidcrystal® Incretins
03/06/2025 18:46
June 3 (Reuters) - Camurus AB CAMX.ST: CAMURUS AND LILLY ENTER COLLABORATION AND LICENSE AGREEMENT FOR LONG-ACTING FLUIDCRYSTAL® INCRETINS CAMURUS AB - ELIGIBLE FOR UP TO $870 MILLION IN MILESTONE PAYMENTS CAMURUS AB - TO RECEIVE UP TO $290 MILLION IN UPFRONT AND MILESTONE PAYMENTS CAMURUS AB - AGREEMENT INCLUDES UP TO FOUR LILLY PROPRIETARY DRUG COMPOUNDS Source text: ID:nWkr3lPcwN Further company coverage: CAMX.ST ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Camurus AB
See all newsBrief: Camurus Receives Approval In Canada For Oczyesa XR
Brief: Executive Sells About £279,000 Of Camurus Shares
Jefferies cuts Ipsen to 'underperform' on Somatuline competition risk
Brief: Camurus Says NDA Resubmission For CAM2029 In Acromegaly Accepted For Review By FDA
Camurus shares rise after Q2 revenue, operating profit beat